Crinetics Pharmaceuticals, Inc. (CRNX) Stock Price & Analysis

Crinetics Pharmaceuticals, Inc. (CRNX) rose 0.00% to USD 84.95 as of September 8, 2026 at 05:45 UTC, according to Nexqual real-time market data.

CRNX last closed at USD 84.95; the session ranged USD 84.92–85.01 on volume of 8,182,078 shares. Market capitalization is —, with a 52-week range of USD 32.3–85.01 (NMS). Source: Nexqual, September 8, 2026 at 05:45 UTC.

Key Statistics (as of September 8, 2026 at 05:45 UTC)

Technical Analysis (CRNX)

Nexqual's technical model rates CRNX "BUY" based on 5 bullish and 2 bearish signals across 101 daily candles, as of September 8, 2026 at 05:45 UTC.

From Crinetics Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)

Key Strengths & Strategy (as disclosed to the SEC)

• Our discovery team has significant expertise in understanding and creating product candidates to influence the dynamic behavior of GPCRs and has developed a number of proprietary methods, techniques and tools that we 5 Table of Contents believe will enable us to efficiently and reliably evaluate newly synthesized molecules.
• We also possess substantial know-how and trade secrets relating to the development and commercialization of our product candidates, including related manufacturing processes and technology, which strengthen and maintain our proprietary position in the field of endocrinology.
• We believe our approach to developing novel small molecule product candidates that uniquely engage peptide hormone GPCRs will enable us to generate orally bioavailable, and potentially more selective, effective and better tolerated therapeutics for patients.
• CRN09682 (non-peptide drug conjugate for SST2 positive solid tumors) We have developed a first-in-class, non-peptide, non-radioactive NDC linking an SST2 agonist with the cytotoxic drug MMAE, via a spacer and a cleavable linker for the treatment of NETs and potentially for use in other solid tumors that express SST2, or SST2+ tumors.

Partnerships

• Paltusotine is also in development for acromegaly in Japan through our licensing agreement with SKK.
• This single-center, in-patient study is in collaboration with the NIDDK of the NIH.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 05:45 UTC. This page is informational and not investment advice.